title: In brief: ketoacidosis with SGLT2 inhibitors.
mesh_terms: D001559:Benzhydryl Compounds / Q000009:adverse effects; D000068896:Canagliflozin / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2; D005960:Glucosides / Q000009:adverse effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007662:Ketosis / Q000139:chemically induced*; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin; C529054:dapagliflozin; C570240:empagliflozin